Trials / Completed
CompletedNCT00741871
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- S*BIO · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB1518 | SB1518 taken orally daily for 28 consecutive days in a 28 day cycle |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2008-08-26
- Last updated
- 2012-04-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00741871. Inclusion in this directory is not an endorsement.